Q&A with Stephen Brown, Chief Operating Officer of Encap Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Stephen Brown, Chief Operating Officer of Encap Drug Delivery

Pharmaceutical Technology
Volume 33, Issue 10

PharmTech:

What is the biggest industry challenge you're now facing?

Brown:




The biggest challenge facing the pharmaceutical and biotechnology industries is to become more efficient. In essence, the industry needs to do more with less. This is fairly obvious, given the financial pressures that are being faced by Big Pharma as major products come off patent and the difficulty that biotechnology companies have in securing funding. Our business is entirely focused on providing pharmaceutical development and manufacturing services to the pharmaceutical and biotechnology community, and our challenge is to provide solutions that make our clients' overall operations more efficient.

PharmTech:

How do you stay abreast of new developments in the industry?

Brown:

It is easy to become blinkered and focused on your own backyard. It is really important to keep in touch with what is going on in the world around you, both in your clients' and competitors' organizations. Having worked for most of my life in pharmaceutical development, I really enjoy networking and keeping in touch with old work colleagues at Sterling Winthrop (Pittsburgh, PA), sanofi aventis (Paris), Chiroscience (Cambridge, England), Celltech (Slough, England), and UCB (Brussels). I also think it is very important to be an active member of professional organizations such as the Academy of Pharmaceutical Sciences and the American Association of Pharmaceutical Scientists.

PharmTech:

Do you see a new industry trend emerging?

Brown:

I see an increasing trend for pharmaceutical and biotechnology companies to set up strategic relationships with service organizations. There will be a move away from a client–provider relationship to more of a partnership where the contract service provider will operate as an extension of the pharmaceutical or biotechnology company. I see this as a great opportunity for the industry and am sure that the new ways of working that will be required will result in greater speed and efficiency in global pharmaceutical development.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here